ab 8 December 2025 Global Research China Healthcare China preclinical CRO expert call takeaways Notable volume & price recovery in Q425; more potential upside in 2026 On 5 Dec, we invited a senior executive from a domestic medium-sized private preclinical CRO firm to share his views. He noted a clear recovery in China's preclinical CRO industry in Q425—the trend turned stronger in the second half of Nov. For projects involving NHP, order inflow in Q425 is up c30% QoQ in volume terms, and up 10-20% sequentia ...

We came across a bullish thesis on Medpace Holdings, Inc. on FluentInQuality’s Substack. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc.'s share was trading at $530.30 as of October 6th. MEDP’s trailing and forward P/E were 39.83 and 36.23 respectively according to Yahoo Finance. 10 Countries with the Longest Life Expectancy in 2023 Pixabay/Public Domain Medpace is a global, full-service clinical research organization (CRO) serving biotech, pharmaceutical, and medica ...